Company & Sponsor Intelligence
Biogen
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting1
Completed0
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT05097131An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
alzheimers · United StatesTERMINATED
alzheimers · United StatesTERMINATED
NCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →